IRLAB Therapeutics AB (publ) (FRA:6IRA)

Market Cap	14.61M -68.0%
Revenue (ttm)	7.74M +69.0%
Net Income	-8.31M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1660
Previous Close	0.1660
Day's Range	0.1654 - 0.1660
52-Week Range	0.1632 - 0.1868
Beta	n/a
RSI	38.25
Earnings Date	Feb 25, 2026

About IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson’s disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson’s and othe...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IRA

Financial Performance

In 2024, IRLAB Therapeutics AB's revenue was 94.63 million, an increase of 1566.57% compared to the previous year's 5.68 million. Losses were -83.13 million, -53.26% less than in 2023.

Financial numbers in SEK